Published in Cancer Chemother Pharmacol on March 11, 2010
Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat (2011) 0.90
Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer (2011) 0.89
Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies. Cancer Res Treat (2012) 0.87
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. Korean J Intern Med (2013) 0.86
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer (2011) 0.84
Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection. BMC Cancer (2012) 0.84
Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma. World J Gastroenterol (2011) 0.80
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Cancer Chemother Pharmacol (2011) 0.77
Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer (2014) 0.77
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer (2016) 0.77
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS One (2014) 0.75
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut (2012) 2.36
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg (2013) 2.19
Robotic gastrectomy as an oncologically sound alternative to laparoscopic resections for the treatment of early-stage gastric cancers. Arch Surg (2011) 2.16
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol (2009) 2.13
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer (2007) 1.85
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Laparoscopic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer. J Am Coll Surg (2008) 1.80
Role of robotic gastrectomy using da Vinci system compared with laparoscopic gastrectomy: initial experience of 20 consecutive cases. Surg Endosc (2009) 1.80
Early gastric cancer of signet ring cell carcinoma is more amenable to endoscopic treatment than is early gastric cancer of poorly differentiated tubular adenocarcinoma in select tumor conditions. Surg Endosc (2011) 1.71
Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol (2002) 1.71
Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures. Ann Surg (2009) 1.71
Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer (2005) 1.70
Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med (2005) 1.70
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat (2007) 1.68
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute. Surg Endosc (2011) 1.64
Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. Ann Surg (2014) 1.61
CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med (2011) 1.59
Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. Ann Surg Oncol (2011) 1.58
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol (2007) 1.53
Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis (2002) 1.53
Intravascular flow patterns in transforaminal epidural injections: a comparative study of the cervical and lumbar vertebral segments. Anesth Analg (2009) 1.51
Frequent mutations of human Mad2, but not Bub1, in gastric cancers cause defective mitotic spindle checkpoint. Mutat Res (2005) 1.51
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer (2011) 1.49
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
Laparoscopic resection of a huge intraluminal gastric submucosal tumor located in the anterior wall: eversion method. J Surg Oncol (2005) 1.46
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Support Care Cancer (2013) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
Metabolic syndrome is an independent risk factor for synchronous colorectal neoplasm in patients with gastric neoplasm. J Gastroenterol Hepatol (2012) 1.41
CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics (2006) 1.41
Participation and conflict in the decision-making process for endoscopic resection or surgical gastrectomy for early gastric cancer. J Surg Oncol (2012) 1.40
Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter (2012) 1.40
Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol (2002) 1.40
Early gastric carcinoma with signet ring cell histology. Cancer (2002) 1.39
Application of minimally invasive treatment for early gastric cancer. J Surg Oncol (2004) 1.37
Advanced gastric carcinoma with signet ring cell histology. Oncology (2007) 1.35
Changes in treatment outcomes of gastric cancer surgery over 45 years at a single institution. Yonsei Med J (2008) 1.34
Safety and efficacy of fast-track surgery in laparoscopic distal gastrectomy for gastric cancer: a randomized clinical trial. World J Surg (2012) 1.31
Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol (2009) 1.30
Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol (2004) 1.29
A case of post-streptococcal glomerulonephritis with diffuse alveolar hemorrhage. J Korean Med Sci (2007) 1.28
Intraoperative portable abdominal radiograph for tumor localization: a simple and accurate method for laparoscopic gastrectomy. Surg Endosc (2010) 1.27
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med (2011) 1.26
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat (2009) 1.25
Application of rpoB and zinc protease gene for use in molecular discrimination of Fusobacterium nucleatum subspecies. J Clin Microbiol (2009) 1.25
Current management and future strategies of gastric cancer. Yonsei Med J (2012) 1.23
Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol (2006) 1.23
Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res (2008) 1.21
Primary tracheal tumors: review of 37 cases. J Thorac Oncol (2009) 1.21
Retracted Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J (2012) 1.20
Complications requiring reoperation after gastrectomy for gastric cancer: 17 years experience in a single institute. J Gastrointest Surg (2008) 1.20
Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol (2010) 1.19
Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol (2008) 1.19
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol (2013) 1.18
Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg (2001) 1.18
Menetrier's disease in korea: report of two cases and review of cases in a gastric cancer prevalent region. Yonsei Med J (2004) 1.18
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology (2011) 1.17
The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. J Surg Oncol (2009) 1.17
Endoscopic resection for undifferentiated early gastric cancer. Gastrointest Endosc (2009) 1.15
Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys (2004) 1.15
Gamma-secretase inhibitor reduces allergic pulmonary inflammation by modulating Th1 and Th2 responses. Am J Respir Crit Care Med (2009) 1.14
Prevalence and characteristics of anemia in the elderly: cross-sectional study of three urban Korean population samples. Am J Hematol (2004) 1.14
Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol (2012) 1.14
Risk factors for lymph node metastasis in undifferentiated early gastric cancer. Ann Surg Oncol (2007) 1.13
Comparison of gastric cancer surgery with versus without nasogastric decompression. Yonsei Med J (2002) 1.12
Robotic versus Laparoscopic versus Open Gastrectomy: A Meta-Analysis. J Gastric Cancer (2013) 1.11